Keyword: U.S. Federal Trade Commission


8. Elanco/Bayer animal health

Exiting animal health is the last and largest piece of adjustment in Bayer’s organizational shake-up launched in November 2018. After weeks of rumor, Bayer finally confirmed on Aug. 20 that it’s selling the franchise to Eli Lilly spinoff Elanco for $7.6 billion.

2. AbbVie/Allergan

When the AbbVie/Allergan deal was unveiled in June, Allergan investors cheered, as AbbVie’s stock price sank. Analysts also have their doubts. While most viewed it as welcome news for Allergan, dubbing it a “graceful exit” for a “beaten-up name,” they raised multiple folds of concerns for AbbVie, the buyer.
Bristol-Myers Squibb

1. Bristol-Myers Squibb/Celgene

The year 2019 kicked off with the biopharma industry’s largest acquisition proposal ever: Bristol-Myers Squibb unveiled it would buy Celgene in a cash and stock deal valued at $74 billion.